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Parkinson disease (PD) is a neurodegenerative disorder particularly
characterized by the loss of dopaminergic neurons in the substantia
nigra. Pesticide exposurehas been associatedwith PDoccurrence, and
we previously reported that the fungicide benomyl interferes with
several cellular processes potentially relevant to PD pathogenesis.
Here we propose that benomyl, via its bioactivated thiocarbamate
sulfoxide metabolite, inhibits aldehyde dehydrogenase (ALDH), lead-
ing to accumulation of the reactive dopamine metabolite 3,4-dihy-
droxyphenylacetaldehyde (DOPAL), preferential degeneration of
dopaminergic neurons, and development of PD. This hypothesis is
supported by multiple lines of evidence. (i) We previously showed
in mice the metabolism of benomyl to S-methyl N-butylthiocarba-
mate sulfoxide,which inhibitsALDHat nanomolar levels.We report
here that benomyl exposure in primary mesencephalic neurons (ii)
inhibits ALDH and (iii) alters dopamine homeostasis. It induces se-
lective dopaminergic neuronal damage (iv) in vitro in primary mes-
encephalic cultures and (v) in vivo in a zebraﬁsh system. (vi) In vitro
cell loss was attenuated by reducing DOPAL formation. (vii) In our
epidemiology study, higher exposure to benomyl was associated
with increased PD risk. This ALDH model for PD etiology may help
explain the selective vulnerability of dopaminergic neurons in PD
and provide a potential mechanism through which environmental
toxicants contribute to PD pathogenesis.
Parkinson disease (PD) is second only to Alzheimer disease asa prevalent neurodegenerative disorder, affecting millions
worldwide. Symptoms result from the progressive degeneration
of neurons, most notably dopaminergic neurons in the substantia
nigra pars compacta. More than half of these neurons are lost by
the time symptoms manifest themselves (1). Despite the identi-
ﬁcation of several genetic variants associated with familial as well
as idiopathic PD, only a small fraction of total risk can be
accounted for genetically (2). Thus, environmental factors al-
most certainly play an important role in PD. Understanding the
relevant mechanisms particularly behind the selective loss of
dopaminergic neurons may provide important clues to explain
PD pathogenesis so that therapies can be developed to slow or
reverse disease progression.
Over the past few decades, epidemiologic studies have consis-
tently reported associations between PD occurrence and rural
living, well water consumption, farming occupations, and pesti-
cide exposure (3–12). Pesticides include diverse chemotypes that
differ greatly in structures and mechanisms through which they
act on target pests or produce chronic low-level exposure effects
more relevant to human disease. Fungicides are among the pes-
ticide classes warranting further investigation as potential con-
tributors to PD pathogenesis (13); therefore, benomyl was selected
for the present study.
Benomyl was widely used for three decades until accumu-
lating toxicological evidence in laboratory mammals of liver
tumors, brain malformations, reproductive effects, and possible
carcinogenesis led the US Environmental Protection Agency to
cancel its registration in 2001 (14), although some countries
continue to use this fungicide. Several relevant mechanisms
suggest benomyl may also contribute to PD pathogenesis. The
fungicidal action of benomyl is thought to result from microtubule
assembly impairment (15), a mechanism that has been implicated
in PD (16). Microtubule inhibitors disrupt the ubiquitin-protea-
some system (UPS) (17) and cause selective dopaminergic cell
damage and aggregation of α-synuclein, the predominant com-
ponent of an intracytosolic Lewy body, which is the pathologic
hallmark of PD (16). Furthermore, benomyl inhibits aldehyde
dehydrogenase (ALDH) activity in liver and brain mitochondria
(18, 19), although ALDH inhibition has not been measured di-
rectly in brains in vivo. The mitochondrial-associated ALDH2 is
of particular interest because it metabolizes toxic aldehydes in
brain tissue, including the dopamine (DA) metabolite 3,4-dihy-
droxyphenylacetaldehyde (DOPAL) (Fig. 1). DOPAL has been
shown to be neurotoxic and has been suggested to contribute to
PD pathogenesis (20–23), although a link with an environmental
toxicant has not been established. The accumulation of DOPAL
resulting from ALDH inhibition offers potential relevance to the
preferential loss of dopaminergic neurons observed in PD.
Benomyl decomposes spontaneously, creating a reservoir for
slow release of carbendazim and butyl isocyanate (BIC) (Fig. 1).
We previously showed that benomyl inhibits ALDH activity in
vivo with indirect evidence in brains as elevated acetaldehyde
levels upon ethanol challenge (18). The ALDH inhibitory activity
is caused by BIC and its downstreammetabolites including S-methyl
N-butylthiocarbamate (MBT), which is further converted by cy-
tochrome P450 (CYP) enzymes to MBT sulfoxide (MBT-SO), a
very potent ALDH inhibitor (18). We have also shown that
benomyl is an inhibitor of 26S UPS activity (24), but here we ﬁnd
that this occurs at micromolar concentrations. The present study
shows that nanomolar concentrations of benomyl metabolite(s)
inhibit ALDH activity, resulting in accumulation of toxic alde-
hydes (e.g., DOPAL) and dopaminergic neuronal loss in vitro and
in vivo. Furthermore, we report an association between benomyl
exposure and PD occurrence in a human population. This
investigation integrates cellular and in vivo models with human
patients and environmental exposure data in the study of PD.
These ﬁndings identify ALDH dysfunction as a plausible pathway
Author contributions: A.G.F., S.L.R., J.E.C., B.R., and J.M.B. designed research; A.G.F., S.L.R.,
A.L., N.P.M., H.A.L., K.C.O., and M.C.S. performed research; J.E.C., M.C., and A.S. contrib-
uted new reagents/analytic tools; A.G.F., S.L.R., N.P.M., L.B., and N.T.M. analyzed data; and
A.G.F., S.L.R., J.E.C., and J.M.B. wrote the paper.
The authors declare no conﬂict of interest.
1To whom correspondence should be addressed. E-mail: ectl@berkeley.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1220399110/-/DCSupplemental.
636–641 | PNAS | January 8, 2013 | vol. 110 | no. 2 www.pnas.org/cgi/doi/10.1073/pnas.1220399110
in PD pathogenesis and potential therapeutic target for developing
disease-modifying therapies.
Results
ALDH Inhibition in Primary Neurons and Mitochondrial Preparations.
We previously reported that benomyl inhibits ALDH activity in
mouse mitochondria (18); we extend the study here to direct
measurement in primary neurons using a cell-based assay in
which ﬂuorescence increases with ALDH activity. Exposure of ex
vivo suspensions of nigral neurons to benomyl for 30 min re-
sulted in concentration-dependent ALDH inhibition (Fig. 2A).
ALDH activity was inhibited by 19 ± 0.4% (P = 4.6 × 10−7, n =
3) at the lowest concentration tested (0.1 μM), progressively
increasing to 35 ± 0.6% inhibition at the highest concentration
tested (20 μM; P = 2.7 × 10−20, n = 10). MBT exposure (10 μM)
inhibited ALDH activity by 12 ± 1% (P = 2.9 × 10−5, n = 5). In
contrast, carbendazim was ineffective at concentrations up to 20
μM (Fig. 2A). We also quantitated the ALDH IC50 values of
benomyl and its metabolites using mitochondria isolated from
rat liver (Fig. 2 B and D). Benomyl and BIC were essentially
equipotent with IC50 values of 0.12–0.14 μM. MBT had an IC50
of 1.3 μM, whereas carbendazim did not inhibit ALDH activity
(Fig. 2 B and D). These results are consistent with those of Staub
et al. for hepatic mitochondria prepared from mice (18).
UPS Inhibition. We previously reported that benomyl is a UPS
inhibitor (24), but the inhibiting moiety was not determined.
Benomyl inhibited the 26S UPS with an IC50 of 5.7 μM after
a 48-h exposure in an SK-N-MC neuroblastoma cell line (Fig. 2
C and D). Carbendazim had the same effect (IC50 = 5.7 μM),
whereas MBT did not inhibit the UPS, suggesting that the car-
bendazim moiety is responsible for benomyl’s inhibition of the
UPS at micromolar concentrations.
Selective Dopaminergic Neurotoxicity in Vitro. Immunocytochem-
istry against tyrosine hydroxylase (TH+) and neuronal nuclei
(NeuN+) was conducted on primary mesencephalic cultures to
determine the toxicities of benomyl and metabolites on dopa-
minergic and total neurons (Fig. 3 A and B). Benomyl was se-
lectively toxic to dopaminergic neurons, resulting in a 24 ± 6%
decrease in TH+ cells at 0.1 μM and a 35 ± 4% decrease at 1 μM
after 48-h exposures (Fig. 3C) with no signiﬁcant loss of total
NeuN+ neurons at either concentration (e.g., 1 μM, 3 ± 14%
change, P = 0.79), demonstrating the selective toxicity of beno-
myl. The total number of NeuN+ neurons (i.e., total neurons) did
not signiﬁcantly change despite the loss of TH+ neurons because
TH+ cells only contributed on the order of 1% of total neurons
counted. MBT exposure (1 μM) resulted in a 27 ± 6% decrease
in TH+ cells (Fig. 3C), comparable to benomyl exposure, and
similarly had no effect on NeuN+ cells. In contrast, carbendazim
exposure alone had no signiﬁcant effect on TH+ or NeuN+
neuron counts, and there was no synergistic effect when cells
were exposed simultaneously to MBT and carbendazim. These
results suggest that benomyl’s neurotoxicity is due to MBT, and
therefore ALDH inhibition, at the concentrations tested.
ALDH Inhibition as a Neurotoxic Mechanism. We hypothesized that
benomyl’s selective toxicity to TH+ neurons was caused by its
effects on DA metabolism. DA is oxidized by monoamine oxidase
(MAO) to form DOPAL, which is then further oxidized to 3,4-
dihydroxyphenylacetic acid (DOPAC) by ALDH (Fig. 1). We
were unable to measure DOPAL concentration ([DOPAL]) di-
rectly because of its instability and very low concentrations in
cultures, so we measured [DA] and [DOPAC] to determine if DA
homeostasis shifted with benomyl treatment. A subset of pri-
mary cultures treated with benomyl was sacriﬁced at 3 h. [DOPAC]
was 42 ± 11% less in benomyl-treated cultures (P = 0.034, n = 16),
and [DA] remained relatively unchanged (1% decrease, P = 0.44),
so [DOPAC]/[DA] was 38 ± 13% less (P = 0.035), consistent with
ALDH inhibition in these neurons. To test if accumulation of
ALDH substrates (i.e., DOPAL) caused benomyl’s neurotoxicity,
DOPAL formation was inhibited with the MAO inhibitor pargy-
line. TH+ neuronal loss was attenuated by 30 ± 9% (P = 0.14, n =
13–14; Fig. 4) in cultures cotreated with pargyline (200 μM) and
benomyl (1 μM). Pargyline completely prevented neurotoxicity in
cultures treated with MBT (1 μM), a less potent ALDH inhibitor
(P = 0.011, n = 14–15). Pargyline alone had no effect on TH+
neuronal counts at this concentration.
α-Synuclein Levels. The major pathologic hallmark of PD is the
formation of Lewy bodies which are comprised primarily of
α-synuclein aggregates. α-Synuclein levels measured using im-
munocytochemistry in surviving dopaminergic neurons did not
change signiﬁcantly in TH+ neurons exposed to benomyl, MBT,
carbendazim, or a combination of MBT and carbendazim.
Selective Aminergic Neurotoxicity in Vivo.Zebraﬁsh have been used
in developmental toxicology studies, and they are now being used
Fig. 1. ALDH inhibition as the proposed mechanism of benomyl-induced
Parkinson disease. Benomyl is efﬁciently metabolized to potent ALDH
inhibitors—BIC, MBT, and particularly MBT-SO—so exposure leads to the
accumulation of the toxic dopamine metabolite DOPAL. This offers a possi-
ble explanation for the selective toxicity to dopaminergic neurons observed
in PD pathogenesis. GSH, glutathione.
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Fig. 2. Inhibitory actions of benomyl and its metabolites. (A) Exposure to
benomyl or MBT, but not carbendazim, inhibited ex vivo ALDH activity in
mesencephalic neurons dissociated from 2-d-old rat pups (n = 3–11). (B)
Benomyl, BIC, and MBT inhibited in vitro mitochondrial ALDH activity (n =
2–8 at each concentration tested). Carbendazim did not signiﬁcantly inhibit
mALDH activity at up to 20 μM (n = 4). (C) Benomyl and carbendazim
inhibited 26S UPS activity in SK-N-MC neuroblastoma cells (n = 4–14 at each
concentration tested), whereas MBT exposure up to 10 μM had no effect (n =
5). (D) Benomyl/BIC/MBT inhibit ALDH activity at lower concentrations than
benomyl/carbendazim inhibit the 26S UPS. Data are expressed as percent
relative to vehicle controls (0.01% DMSO), except for 26S UPS inhibition
which is relative to treatment with the 26S UPS inhibitor lactacystin (5 μM).
*P < 0.01, **P < 0.0001; benomyl (○), BIC (◇), MBT (☐), carbendazim (Δ).
mALDH, mitochondrial aldehyde dehydrogenase; 26S UPS, ubiquitin-pro-
teasome system.
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to investigate neurotoxicity (25). To test the speciﬁcity of beno-
myl neurotoxicity in a vertebrate system, a model was developed
using transgenic zebraﬁsh (Danio rerio) lines that label speciﬁc
neuronal populations with GFP that can be visualized because
embryos are transparent. Zebraﬁsh have a well-developed do-
paminergic system. The anterior clusters shown in Fig. 5 A and B
correspond to aminergic neurons in the olfactory bulb and tel-
encephalon of ETvmat2:GFP zebraﬁsh (26) embryos; the pos-
terior clusters contain the diencephalon. These clusters are
predominantly dopaminergic, although they also include some
(nor)adrenergic neurons (27). Exposure to 1 μM benomyl from
5 h until 120 h postfertilization resulted in a 24 ± 9% decrease in
VMAT2+ (vesicular monoamine transporter) neuronal counts in
anterior clusters (P = 0.041, n = 19; Fig. 5G) and an 18 ± 9%
decrease in diencephalic clusters (P = 0.15), constituting an
overall 22 ± 8% decrease in VMAT2+ neurons (P = 0.043).
Fluorescence similarly trended lower by 25 ± 13% (anterior, P =
0.16; Fig. 5H), 38 ± 13% (diencephalon, P = 0.061), and 27 ± 12%
(overall, P = 0.089). Tg(isl1[ss]:Gal4-VP16,UAS:EGFP)zf154
embryos (28) that were exposed to the same conditions exhibited
no signiﬁcant differences in neuron counts or ﬂuorescence in
Rohon-Beard (Fig. 5 C and D) or trigeminal (Fig. 5 E and F)
sensory neurons. Even the complex axons were unaffected, adding
further evidence that benomyl is toxic to dopaminergic neurons in
a selective manner (Fig. 5 G and H). Benomyl exposure under
these conditions was not lethal to zebraﬁsh embryos, but swim-
ming behavior was altered. After 2 wk of exposure, benomyl-
treated zebraﬁsh exhibited a 45 ± 10% deﬁcit in spontaneous
swimming distance versus unexposed zebraﬁsh (P = 0.006, n = 11–
15), suggesting that benomyl’s selective toxicity to dopaminergic
neurons has functional signiﬁcance in vivo.
Epidemiologic Association. Potential association between benomyl
exposure and PD occurrence was investigated in an epidemio-
logic study to determine the possible relevance of these ﬁndings
that benomyl exposure resulted in selective dopaminergic neu-
ronal damage in vitro and in vivo. These analyses included 360
PD patients (“cases”) and 754 neurologically normal subjects
(“controls”) (Table S1). PD risk increased 67% for individuals
with estimated ambient benomyl exposure at their workplace
equal to or above the median level (OR = 1.67, 95%CI: 1.19–
2.34; P = 0.0027; Table S2). This risk increased to almost twofold
for those with estimated exposures in the highest quartile (OR =
1.97, 95%CI: 1.29–3.02; P = 0.0017), revealing a dose–response
trend (P = 0.0019; Table 1). There was no trend between ben-
omyl exposure and PD based on residential addresses. These
analyses had been adjusted for known PD risk factors (e.g., age,
sex), and the ﬁndings did not change in sensitivity analyses
adjusting for race/ethnicity or family history of PD, or when
excluding subjects potentially overrepresenting particular resi-
dential clusters or missing 1 or more years of occupational data.
Discussion
PD etiology has proven very difﬁcult to determine using various
genetic models and epidemiologic studies. It likely includes
a combination of genetic and environmental contributions, so
investigations involving environmental toxicants may help eluci-
date the complex mechanisms at play. The recognition of new
epidemiologic contributors to PD etiology expands the consid-
eration of possible mechanisms involved. The proposed envi-
ronmental contributor here is benomyl, recognized in an
epidemiologic investigation, and this suggests ALDH inhibition
in humans contracting PD. Because direct causality of environ-
mental risk factors cannot be tested in humans, this investigation
sought to determine if exposure in experimental models could
recapitulate some of the pathologic features of PD. Here we
report selective dopaminergic neuronal damage in both an in
vitro system (primary cultures) and an in vivo zebraﬁsh model.
There was signiﬁcant loss in zebraﬁsh aminergic neurons mea-
sured both by neuron counts and ﬂuorescence, whereas the
nonaminergic trigeminal and Rohon-Beard sensory neurons
remained intact after benomyl exposure. A selective loss of do-
paminergic neurons was similarly observed in mesencephalic
cultures exposed to benomyl, reﬂecting the preferential loss of
dopaminergic neurons characteristic of PD.
Benomyl’s action as a fungicide is thought to be due to its
ability to impair microtubule assembly, interfering with mitosis
and other processes (29, 30). Microtubule inhibitors such as
nocodazole and rotenone also inhibit the UPS (17). We found
that the carbendazim moiety of benomyl, a known microtubule
inhibitor, confers benomyl’s UPS inhibitory activity. However, it
is unlikely that microtubule or UPS dysfunction is responsible for
benomyl’s toxicity observed in primary cultures or zebraﬁsh,
given the low concentrations used relative to its IC50 (5.7 μM).
[Because concentrations in the range of 1.3–50 μM are necessary
for benomyl’s use as a fungicide in the environment (31–33), we
used a conservative concentration range (0.1–1 μM) in primary
cultures and zebraﬁsh to enhance relevance to actual exposures
for humans.] Furthermore, carbendazim had no effect on neu-
ronal survival at 1 μM, whereas MBT recapitulated benomyl’s
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Fig. 3. Dopaminergic neuronal damage in primary mesencephalic cultures
exposed to benomyl or its metabolites. Representative ﬁeld of view (20×)
shows untreated immunoreactive (A) dopaminergic neurons (TH+) and (B)
neuronal nuclei (NeuN+). (C) Benomyl neurotoxicity was recapitulated by
MBT exposure, whereas carbendazim was not toxic to TH+ neurons at 1 μM.
NeuN+ counts were unaffected by any treatment. Because MBT is either the
proximal or penultimate benomyl metabolite that inhibits ALDH activity,
there appears to be an association between neuronal damage and ALDH
inhibition; proteasomal inhibition by the carbendazimmoiety is not sufﬁcient
to kill cells under the same conditions. Data are expressed as percent relative
to vehicle controls (0.01% DMSO). *P < 0.05, **P < 0.01, ***P < 0.0001.
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Fig. 4. Monoamine oxidase (MAO) inhibitor protects against neurotoxicity
because of DOPAL accumulation. Neuronal loss resulting from 1 μM benomyl
or MBT exposure was mitigated by cotreatment with the MAO inhibitor
pargyline (200 μM, n = 13–28). Because MAO inhibition reduces the me-
tabolism of dopamine to DOPAL, this suggests that DOPAL is toxic to do-
paminergic neurons and that benomyl is toxic via DOPAL accumulation as
a result of ALDH inhibition. Data are expressed as percent relative to vehicle
controls (0.01% DMSO). *P = 0.0027, **P = 2.4 × 10−4, ***P = 6.1 × 10−5.
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toxicity. Because benomyl and its metabolite MBT, but not
carbendazim, inhibit ALDH activity at the concentrations used,
ALDH inhibition likely confers benomyl’s neurotoxicity. Addi-
tional support for the potential role of toxicant-induced ALDH
inhibition in the pathogenesis of PD comes from a report from
Wey et al. that describes TH+ neuronal loss, DOPAL accumu-
lation, and motobehavioral deﬁcits in mice lacking cytosolic and
mitochondrial ALDH (Aldh1a1−/−xAldh2−/−) (34). Their work
demonstrated that ALDH inhibition can recapitulate some
pathologic aspects of PD in an in vivo model. It is remarkable
that the environmental impact of benomyl exposure in the present
work yielded similar results in vitro and in vivo as their targeted
genetic approach. This is in contrast to another fungicide, ziram,
which increases α-synuclein levels and damages dopaminergic cells
by inhibiting E1 ligase activity in the UPS (35). Benomyl appears
to act via a novel mechanism (ALDH inhibition), damaging do-
paminergic cells via alterations in DA homeostasis, independent
of α-synuclein.
Our observed alterations in DA metabolites after benomyl
exposure add further evidence that ALDH inhibition is the cause
of benomyl’s neurotoxicity. Goldstein et al. similarly found that
striatal [DOPAL]:[DA] was four times higher in postmortem PD
brains (36). They also observed decreased VMAT2 activity (37).
Burke et al. reported that DOPAL is 400-fold more toxic to
dopaminergic neurons in vivo than its precursor (i.e., DA) or its
ALDH product (i.e., DOPAC) (21–23), potentially because of
OB 
& 
Te De 
LC 
OB 
& 
Te De LC 
b a 
c d 
e f 
0
20
40
60
80
100
N
eu
ro
ns
 [%
]
** ** 
OB & Te
VMAT2+
De
VMAT2+
Combined
VMAT2+
Rohon-
Beard
Trigeminal
0
20
40
60
80
100
Fl
uo
re
sc
en
ce
 [%
]
* * 
g 
h 
Fig. 5. Aminergic neuronal damage in Danio rerio
embryos exposed to benomyl. Representative confocal
images of zebraﬁsh embryos (A, C, and E) unexposed
or (B, D, and F) bathed in 1 μM benomyl from 5 h until
120 h postfertilization are shown. (G) Neuronal counts
(A and B) decreased in VMAT2+ anterior and di-
encephalic clusters of ETvmat2:GFP zebraﬁsh exposed
to benomyl (solid bars) but were unaffected in (C and
D) Rohon-Beard and (E and F) trigeminal neurons in
Tg(isl1[ss]:Gal4-VP16,UAS:EGFP)zf154 zebraﬁsh. (H) Mea-
surement of total ﬂuorescence yielded similar results.
Data are expressed as percent relative to vehicle con-
trols (0.01% DMSO). *P < 0.1, **P < 0.05. De, dien-
cephalon; LC, locus coeruleus; OB, olfactory bulb; Te,
telencephalon.
Table 1. Associations between estimated ambient occupational or residential benomyl
exposures and PD risk in the UCLA PEG Study
Exposure, n (%)* Cases (n = 360) Controls (n = 754) OR (95%CI)† P value‡
Occupational
No 217 (60.3) 531 (70.4) Reference
First quartile 23 (6.4) 55 (7.3) 0.90 (0.53–1.53) 0.69
Second quartile 26 (7.2) 51 (6.8) 1.07 (0.64–1.79) 0.81
Third quartile 40 (11.1) 62 (8.2) 1.38 (0.88–2.17) 0.16
Fourth quartile 54 (15.0) 55 (7.3) 1.97 (1.29–3.02) 0.0017
Trend P value 0.0019
Residential
No 209 (58.1) 467 (61.9) Reference
First quartile 31 (8.6) 71 (9.4) 0.87 (0.54–1.40) 0.56
Second quartile 41 (11.4) 72 (9.5) 1.14 (0.73–1.77) 0.57
Third quartile 31 (8.6) 73 (9.7) 0.79 (0.49–1.27) 0.34
Fourth quartile 48 (13.3) 71 (9.4) 1.20 (0.78–1.86) 0.40
Trend P value 0.071
CI, conﬁdence interval; OR, unconditional logistic odds ratio.
*Exposure quartiles deﬁned using distributions of exposed controls, separately for occupational or residential
estimates. Two cases and one control with incomplete occupational data and one case with incomplete residen-
tial data were assumed to be unexposed.
†Adjusted for age (continuous), sex (male/female), smoking status (current/former/never), county (Fresno/Kern/
Tulare, California), and education (<12 y/=12 y/>12 y).
‡For multiple testing considerations, 8 tests were performed so a P value of 0.006 was considered statistically
signiﬁcant.
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the formation of reactive radicals and quinones (38). VMAT2
inhibition could provide a larger reservoir of cytosolic DA,
making neurons more susceptible to DOPAL toxicity. Thus,
benomyl’s selective toxicity to dopaminergic neurons can be
explained by ALDH inhibition leading to toxic DOPAL accu-
mulation. Consistent with this hypothesis, reducing DOPAL
synthesis with an MAO inhibitor mitigated benomyl’s toxicity.
The present work reveals ALDH inhibition as a toxicant-in-
duced neurotoxic mechanism and adds an epidemiologic asso-
ciation that suggests the relevance of this mechanism in a human
population. The University of California Los Angeles (UCLA)
Parkinson’s Environment and Genes (PEG) Study is unique in
its ability to use data from state-mandated commercial agricul-
tural Pesticide Use Reporting forms to overcome subject recall
bias and to determine associations with speciﬁc toxicants in
a heavy pesticide use region of California. Here we show that
chronic exposure to ambient benomyl at the workplace was as-
sociated with 67% to almost twofold increases in risk of de-
veloping PD after adjusting for known PD risk factors. Analyses
based on workplace addresses potentially incorporate the best
estimates of subjects’ ambient benomyl exposures because pes-
ticide applications occur during the workday when subjects
would have been at their workplace rather than their residence.
Notably, this model only estimates relative ambient exposures
and does not take into account other routes of exposures such as
occupational handling of pesticides and drinking well water, both
associated with increased risk of PD, which could exacerbate the
estimated risk even further (39–41). We have used this method
to report positive associations between PD onset and exposures
to ziram, maneb, and paraquat (42, 43). In a logistic regression
model that includes our benomyl variable and a variable for the
combination of ziram, maneb, and paraquat, the benomyl as-
sociation remains robust and the conﬁdence interval excludes
the null.
Concluding Remarks
Benomyl was widely used in the United States for three decades
until toxicological evidence revealed its potential to elicit liver
tumors, brain malformations, reproductive effects, and carcino-
genesis. In 2001, the registrants of benomyl voluntarily canceled
their commercial use registrations, and the US Environmental
Protection Agency has not granted additional registrations (14).
The present work adds a PD association to these toxicological
investigations and demonstrates the possibility for long-lasting
toxicological effects of pesticide use even a decade after chronic
exposure. This work suggests that exposure to an environmental
toxicant may inhibit ALDH sufﬁciently to damage dopaminergic
neurons and increase the risk of exposed humans developing PD.
This ﬁnding may be generalizable to all PD patients, so aug-
menting ALDH activity may be a potential therapeutic target for
designing disease-modifying therapies for PD regardless of en-
vironmental exposures.
Methods
ALDH Activity Assays. All procedures using animals were approved by the
UCLA Animal Research Committee. Mesencephalic neurons (postnatal day 2)
were dissected and dissociated as described for primary cultures below. In-
stead of plating, neurons were resuspended in buffer from the Aldeﬂuor kit
(STEMCELL Technologies). Aldeﬂuor was added (1 μL/mL) to the neuronal
suspension, and 300-μL aliquots were immediately transferred to culture
tubes containing 3 μL of test compound solutions, resulting in ﬁnal con-
centrations of 100 nM–20 μM. Culture tubes were incubated at 37 °C for 30
min with periodic gentle shaking. Using FACS (XL-MCL, Beckman), cells were
gated by forward- and side-scatter, and intracellular green ﬂuorescence was
measured on channel FL1. ALDH inhibition was determined by comparing
ﬂuorescence in the presence or absence of test compounds.
Rat hepatic mitochondria were isolated using published protocols (44, 45).
These preparations (10 μL) were exposed to test compounds for 5 min in 170
μL of 50 mM pyrophosphate buffer (pH 9.0), 50 mM NAD+, 0.1 mM pyrazole,
0.5% (wt/vol) sodium deoxycholate, and 2 μM rotenone (added in 2.7 μL
methanol). Absorbance at 340 nm was monitored for 10 min at 5-s intervals
after 1 mM acetaldehyde (20 μL) was added (SpectraMax 340PC384 Absorbance
Microplate Reader, SoftMax Pro software, Molecular Devices). ALDH activity
was determined from the slope as the increase in absorbance over time from 1
to 3 min.
26S UPS Activity Assay. The 26S UPS activity was determined by FACS as
previously described (24). Brieﬂy, neuroblastoma SK-N-MC cells transfected
with an EGFP–degron fusion protein and passaged multiple times were ex-
posed to test compounds for 48 h at 2 mL/well before FACS analysis (Beckman
XL-MCL). UPS inhibition was inferred from high ﬂuorescence corresponding to
the level of EGFP–degron fusion protein that was not selectively degraded by
the proteasome (46).
Primary Neuronal Cultures. Primary neuronal cultures were prepared using
a protocol adapted from Rayport et al. and previously described (35, 47).
Brieﬂy, mesencephalic cells containing the substantia nigra pars compacta
(excluding the ventral tegmental area) were dissected from coronal sections
of brains from postnatal day 1 or 2 rat pups, dissociated in papain, and
plated onto glial cells at densities of 4 × 105 per coverslip. Cultures were
grown for 6–8 d and then treated by exchanging 1 mL of the media in each
plate with 1 mL of fresh media amended with test compound(s) and vehicle
(0.01% DMSO).
Cultures after 48-h treatment were ﬁxed in paraformaldehyde (4%wt/vol)
for 30 min, washed with PBS, blocked with normal donkey serum (5% vol/
vol) and Triton X-100 (0.5% vol/vol) in PBS for 1–2 h, incubated with anti-
bodies against TH (1:1,500, anti-rabbit, Calbiochem) and NeuN (1:200, anti-
mouse, Millipore) overnight at 4 °C, washed with 3× and 1× PBS, incubated
with Alexa Fluor 488 (1:200, Invitrogen) and 555 (1:1,500, Invitrogen) sec-
ondary antibodies at room temperature for 2 h, and washed with Tween-20
(0.1%) in PBS and then with PBS before coverslipping. All TH-immunoreac-
tive neurons were counted, and NeuN-immunoreactive neuron counts were
estimated for each coverslip from neurons quantiﬁed in ﬁve representative
ﬁelds of view using a 20× objective. Quantiﬁcation was determined by
blinded raters. Some cultures were incubated with antibodies against TH
and α-synuclein (1:500, anti-mouse, BD Biosciences). Relative levels of
α-synuclein in TH+ cells were determined as previously described (35), using
the GNU Image Manipulation Program (GIMP 2.6).
To determine cell levels of dopamine and its metabolites, some cultures
were extracted with perchloric acid (100 mM) and EDTA (0.1% wt/vol) and
stored at −80 °C until HPLC analysis. Samples were separated on a C18 reverse
phase column (TSKgel Super ODS 2 μm particle size, 10 × 2.1 mm, maintained
at 33 °C, Tosoh Bioscience) using a mobile phase (2.5% methanol, 100 mg/L
sodium-1-octane sulfonate, 42 mM citric acid, 38 mM sodium acetate, 50 mg/L
EDTA) pumped at 0.2 mL/min (LC-10AD pump, Shimadzu). Monoamines and
metabolites were oxidized on a glassy carbon electrode against an Ag/AgCl
reference (Antec Leyden) with an applied potential of 0.75V. Data were col-
lected using EzChrom software (Agilent).
In Vivo Studies. Zebraﬁsh embryos were bathed in 1 μM benomyl or vehicle
(0.01% DMSO) in E3 medium for zebraﬁsh embryos from 5 h until 120 h
postfertilization, anesthetized using tricaine methanesulfonate (0.02%),
ﬁxed in paraformaldehyde (4%) overnight, and mounted in agarose (1.2%
wt/vol) for confocal imaging at 20× magniﬁcation. Zebraﬁsh expressing GFP
tagged to vesicular monoamine transporter protein (ETvmat2:GFP) were
used to identify VMAT2+ (dopaminergic, (nor)adrenergic, serotonergic)
neurons in whole embryos (26). Approximately 100 optical sections were
gathered for each embryo, spaced 1.34 μM apart, using a Zeiss LSM 5 Pascal
inverted microscope. Images were reconstituted, and clusters of anterior
(including olfactory bulb and telencephalon) and diencephalic neurons were
identiﬁed for analyses. Peripheral sensory neurons (trigeminal and Rohon-
Beard) were visualized using the Tg(isl1[ss]:Gal4-VP16,UAS:EGFP)zf154 trans-
genic line, which has been referred to as Tg(sensory:GFP) (28). Approxi-
mately 60 optical sections were spaced 3 μM apart, using a Zeiss LSM 510
inverted microscope. Cells were counted blindly in 3D projections, and
ﬂuorescence in composite images was measured blindly using ImageJ (Na-
tional Institutes of Health). Spontaneous zebraﬁsh movement was moni-
tored with ZebraLab (Viewpoint Life Sciences, Inc.). Total distance was
measured by tracking individual embryos for 30 min. Embryos were con-
sidered immobile at 0–2 mm/s.
Epidemiologic Study. This investigation was conducted as part of the UCLA
PEG Study (Table S1). Written informed consent was obtained from all en-
rolled subjects, and all procedures were approved by the UCLA Human
Subjects Committee. Subject recruitment methods and case deﬁnition cri-
teria have been described in detail (42). Pesticide exposure assessments were
performed using a geographic information system–based computer model
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incorporating Pesticide Use Reporting forms that have been mandated by the
California Department of Pesticide Regulation since 1974 and provide in-
formation on the location, date, and amount of pesticide in each commercial
application (43, 48–50). Geocoded lifetime occupational and residential
addresses were considered separately. Ambient exposure was assumed to be
proportional to the amount of pesticide applied to crop acreage within a 500-m
radius surrounding the subject’s address averaged over the 26-y period (1974–
1999). Exposure was categorized by the median in controls, resulting in a three-
level variable (unexposed, exposure below the median, exposure equal to or
above the median). For quartile analyses, exposure was categorized by quartiles
in exposed controls, resulting in a ﬁve-level variable (unexposed, four quartiles).
Statistical Analyses. Demographic characteristics were compared for deviation
from expected by χ2 test (categorical variables) or for difference in mean by t
test (age). Logistic regression analyses were performed on the epidemiologic
data using SAS 9.1 (SAS Institute Inc.). Odds ratios and 95% conﬁdence
intervals were estimated after adjusting for age (continuous variable), sex
(male/female), county of residence (Fresno/Kern/Tulare, California), education
(less than 12 y of schooling/12 y or completion of general education de-
velopment test/more than 12 y), and smoking status (current/former/never).
Sensitivity analyses were performed to assess the effects of adjustments for
race (Caucasian/non-Caucasian) and family history of PD (ﬁrst-degree family
history present/absent). Additional sensitivity analyses were performed ex-
cluding 23 controls who had lived in the same cluster as another control at the
time of recruitment for at least 2 y before 1999, and excluding 44 cases and 95
controls who were missing one or more occupational addresses from 1974 to
1999. For trend tests, quartile categories were assigned scores of 0, 1, 2, 3, or 4
and entered into the logistic regression equation as a linear term. The Wald
statistic was used as a test for linear trend of the odds ratio. In biochemical
assays, IC50 values were determined using sigmoidal curve ﬁts of percent in-
hibition at varying concentrations (PRISM 5, GraphPad). For all other analyses,
statistical signiﬁcance was determined using a paired t test.
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